ResApp Health (ASX:RAP) - Managing Director & CEO, Dr Tony Keating
Managing Director & CEO, Dr Tony Keating
Source: ResApp Health
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Digital health company ResApp Health (RAP) has signed an agreement with Medgate AG to run ResAppDx in Medgate’s telemedicine services
  • The joint development and pilot agreement will last for six months and see ResApp’s app tested in Medgate’s telemedicine services across Europe
  • The companies expect to spend two months integrating the app into Medgate’s services, before beginning the three month trial in early 2021
  • ResApp won’t be remunerated for the pilot, but it is expected both businesses will enter into negotiations on a future cost model
  • Shares in RAP are trading up 9.3 per cent for 9.4 cents each

ResApp Health (RAP) has signed an agreement to run its smartphone-based
acute respiratory diagnostic test in Medgate AG’s telemedicine services.

Medgate is a leading provider of digital health in Europe and also runs the region’s largest telemedical centre in Switzerland, with 500 employees.

The joint development and pilot agreement between the digital health company and Medgate will last for six months.

For the first two months of the agreement, the companies will focus on building RAP’s ResAppDx into Medgate’s services.

From there, a three-month pilot will be carried out, testing the integration of the two programs.

The pilot is expected to begin in early 2021, with both Medgate and ResApp to jointly assess its success on a number of key indicators.

Commenting on the pilot, RAP CEO and Managing Director Tony Keating said he was very pleased to have entered into this agreement.

“Medgate is a well-known and respected organisation and we look forward to working with them to deliver our ResAppDx product to their customers,” he said.

“This partnership is ongoing validation of our offering and will potentially allow the company to pursue a large market opportunity in Europe, as well as in Asia and the Middle East where Medgate also has operations,” he added.

ResApp won’t be paid for participating in the pilot, but both parties are expected to enter into negotiations on a future cost model.

Shares in RAP are trading up 9.3 per cent for 9.4 cents each at 11:14 am AEDT.

RAP by the numbers
More From The Market Online
advanced mri or ct scan medical diagnosis machine at hospital lab

Imricor raises $35M to pursue growth and expansion into Australia and NZ

Imricor Medical Systems Ltd intends to use the capital raising's funds to support a three-pronged growth…
Abstract visualization of a brain hemorrhage from an MRI perspective, with vivid colors marking the hemorrhagic areas against the brain's grayscale anatomy.

Trial for Alterity’s neurodegenerative drug ATH434 shows reduced disability

An interim trial testing the effects of ATH434 on patients with MSA has yielded positive results…
The Market Online Video

Recce scores US$2M deal from US Department of Defense for burn wound infections gel

Recce Pharmaceuticals Ltd has been funded to the tune of US$2M by the US Department of…
AI gen cancer cell

Immutep reports strong response rate from immunotherapies treating carcinomas

Immutep Ltd has reported a slew of positive results from a trial to assess a combination…